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Abstract Over the past decade, many lines of investigation
have shown that receptor-mediated signaling exhibits
greater diversity than previously appreciated. Signal diver-
sity arises from numerous factors, which include the
formation of receptor dimers and interplay between different
receptors. Using adenosine A1 receptors as a paradigm of G
protein-coupled receptors, this review focuses on how
receptor-receptor interactions may contribute to regulation
of the synaptic transmission within the central nervous
system. The interactions with metabotropic dopamine,
adenosine A2A,A 3, neuropeptide Y, and purinergic P2Y1
receptors will be described in the first part. The second part
deals with interactions between A1Rs and ionotropic
receptors, especially GABAA, NMDA, and P2X receptors
as well as ATP-sensitive K
+ channels. Finally, the review
will discuss new approaches towards treating neurological
disorders.
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Abbreviations
A1R adenosine A1 receptor
A2AR adenosine A2A receptor
A2BR adenosine A2B receptor
A3R adenosine A3 receptor
2-CA 2-chloro-adenosine
CHA N
6-cyclohexyladenosine
Cl-IB-
MECA
N
6-(3-iodobenzyl)adenosine-5′-
N-methyluronamide
CPA N
6 cyclopentyladenosine
8-CPT 8-cyclopentyl-1,3-dimethyl-xanthine
D1R dopamine D1 receptor
D2R dopamine D2 receptor
DIDS chloride channel blocker
DPCPX 1,3-dipropyl-8-cyclopentylxanthine
EPSPs excitatory postsynaptic potentials
[F7,P34]
pNPY
Y1R agonist
GIRK1–4 inward rectifying K
+ channels
GPCR G protein-coupled receptor
GRAFS glutamate, rhodopsin, adhesion, fizzled/taste
and secretin-like GPCRs
IP3 inositol 1,4,5-triphosphate
IPSPs inhibitory postsynaptic potentials
KATP ATP-sensitive K
+ channels
LTP long-term potentiation
MPTP methylphenyltetrahydropyridine
MRS-1191 [3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-
6-phenyl-1,4-(+/-)-dihydropyridine-3,
5-dicarboxylate]
NHE1 Na
+/H
+ exchange
NPY neuropeptide Y
PLA phospholipase A
PLC phospholipase C
PSPs postsynaptic potentials
R-PIA (R)-N6-(2-phenylisopropyl)adenosine
SKF 38393 (+/-)-1-phenyl-2,3,4,5-tetrahydro-(1H)-
3-benzazepine-7,8-diol hydrobromide
VDCC voltage-dependent Ca
2+ channels
Y1–5R neuropeptide Y1–5 receptor
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The vertebrate central nervous system (CNS) is character-
ized by a dynamic interplay between signal transduction
molecules and their cellular targets. Modulation of synaptic
transmission by metabotropic or ionotropic receptors is an
important source of control and dynamical adjustment in
synaptic activity.
Recent studies have provided new insights into the role
of ligand-gated ion channels in modifying synaptic trans-
mission. Along with a growing list of different types of pre-
and postsynaptic ionotropic receptors and the cell types that
express them, there have also been advances in character-
izing the modulatory mechanisms of the receptors that link
to receptor activation. This is important due to the
convergence of data from biochemical, molecular, and
electrophysiological studies, implicating ionotropic recep-
tors in the effects of psychoactive and addictive drugs.
G protein-coupled receptors (GPCRs) make up the largest
and most diverse family of membrane receptors in the
human genome, relaying information on the presence of
diverse extracellular stimuli to the cell interior. An estimated
1% of the mammalian genome encodes for GPCRs, and
about 450 of the approximately 950 predicted human
GPCRs are thought to be receptors for endogenous ligands
[1]. The manipulation of transmembrane signaling by
GPCRs may constitute the most important therapeutic
target in medicine. Nearly 40% of all current therapeutic
drugs target GPCRs [2].
All known GPCRs share a common architecture of seven
membrane-spanning helices connected by intracellular and
extracellular loops. Drugs acting on GPCRs have been
classified as agonists, partial agonists, or antagonists based
on a “two-state model of receptor function.” Since experi-
mental evidence pointed out the impossibility of explaining
the operation of GPCRs without considering dimers as the
minimum structure for many GPCRs the “two-state dimer
receptor model” was developed based on the communication
between the two subunits of the receptor dimmer [1, 3, 4].
This model is an extension of the “two-state model of re-
ceptor function” but considers dimeric structures able to bind
one molecule to the orthosteric center in each monomer.
GPCR signaling is subject to extensive negative regula-
tion through receptor desensitization, sequestration, and
downregulation, termination of G protein activation by
GTPase-activating proteins, and enzymatic degradation of
second messengers. Additional protein-protein interactions
positively modulate GPCR signaling by influencing ligand
binding and specificity.
Multiprotein complexes mediate most cellular functions.
In neurons, these complexes are directly involved in the
neuronal transmission, which is responsible for learning,
memory, and developments. The first publication in this
direction came from Hökfelt’s group in 1983. The publica-
tion describes how substance P may modulate the high-
affinity serotonin (5-HT) binding site in a spinal cord
membranepreparation[5]. Over the past decade, the number
and outcomes of interactions between receptors have
increased continuously [6]. Recent studies have demonstrat-
ed close physical interactions where activation of one
receptor affects the function of the other.
Adenosine is an endogenous purine nucleoside that has
evolved to modulate many physiological processes. Extra-
cellular adenosine mostly originates from release of
intracellular adenosine and from release and extracellular
breakdown of cAMP and ATP by ecto-5′-nucleotidase and
phosphodiesterase [7]. Cellular signaling by adenosine
occurs through four known adenosine receptor subtypes
(A1Rs, A2ARs, A2BRs, and A3Rs), all of which are seven-
transmembrane-spanning GPCRs. Of the four known
adenosine receptors, A1Rs and A2ARs are primarily
responsible for the central effects of adenosine, especially
in modulating synaptic transmission [8]. Adenosine can act
on A1Rs to depress transmitter release and neuronal
sensitivity to the transmitter [9, 10]. As a result, the A1Rs
are important in the regulation of synaptic plasticity,
playing a role in determining the amplitude of long-term
potentiation or long-term depression [11].
There are numerous reviews that describe regulation of
brain adenosine levels, adenosine receptors, their cellular
and subcellular localization, signaling pathways, and func-
tion in the brain under physiological and pathophysiological
conditions as well as selective receptor agonists and antag-
onists. Using A1Rs as a paradigm of GPCRs, this review
focuses on how receptor-receptor interactions contribute to
regulatory processes within the central nervous system.
Considering the various types of receptors, one may
expect to find three principle paths of receptor interaction:
(1) interactions between ionotropic receptors, (2) interac-
tions between a metabotropic receptor and an ionotropic
receptor, and (3) interactions between metabotropic recep-
tors. The examples mentioned below stem from the second
and third type of interaction. Interactions with metabotropic
dopamine receptors as well as A2A,A 3, NPY, and P2Y1
receptors will be described in the first part. The second part
deals with interactions between A1Rs and ionotropic
receptors, especially the GABAA, NMDA, and P2X
receptors as well as ATP-sensitive K
+ channels. Finally,
new approaches for neurological disorders will be discussed.
Functional interactions with metabotropic receptors
Two forms of GPCR classification exist. There is the histo-
rical division into three main families: (1) rhodopsin-like
family which includes adenosine receptors, (2) secretin-like
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The families share some basic similarities—the seven-
transmembrane-spanning domains, intracellularly located
C terminus, and extracellularly residing N terminus. Differ-
ences between the families arise in the length of the intra-
cellular and extracellular termini and amino acid sequences,
disulfide bridge linking, and conserved domains. Five
different groups can be classified by applying phylogenetic
analyses. The GRAFS system distinguishes between gluta-
mate, rhodopsin, adhesion, fizzled/taste, and secretin-like
GPCRs [12].
The agonist binding on the receptor results in coupling
to heterotrimeric G proteins and regulates a variety of cell
responses. In brief, an exchange of G protein-bound GDP
to GTP occurs, and the heterotrimer dissociates into the α
subunit and the βχ dimer. The resulting products activate or
inhibit effectors independently from each other. Currently,
16 different genes encode G protein α subunits, five genes
encode β subunits, while 14 genes encode χ subunits [13].
The α subunits can be categorized into four basic groups:
the stimulatory Gas family couples to adenylate cyclase and
increases cAMP levels, whereas the inhibitory Gαi=0 family
acts in the opposite way. Moreover, the Gαq=11 family
activates the phospholipase Cb (PLCb), and lastly, the
Gα12=13 family which regulates Rho proteins. Gb7 dimers
are capable of triggering effects on inward rectifier K
+
channels (GIRK1–4), voltage-dependent Ca
2+ channels
(VDCC), and phospholipase A2 (PLA2), PLCb, and the
Na
+/H
+ exchanger (NHE1). Thus, it is not surprising that
GPCRs are such interesting candidates in current drug
research with their amazing potential in affecting signaling
events. A single GPCR possesses the potential to activate
more than just one signaling pathway [12]; for example,
activation of A1Rs includes coupling to Gαi=0 and increas-
ing of IP3 level [14, 15]. Furthermore, homodimerization
and heterodimerization are common paths of interaction
and have been described in A1Rs and the A2Rs several
times [16–18]. In addition, functional interactions on the
A1R without receptor assembling have already been
revealed [19, 20], or are currently being elucidated. The
next paragraphs will deal with a few selected examples of
this limitlessly wide topic.
Relationship between A1Rs and A3Rs
The A3R was the latest receptor subtype of the adenosine
receptor family to be identified [21], and its functional role
is still controversially discussed. Several findings indicate
neuroprotective as well as neurotoxic action depending on
experimental approach [22–29]. A3Rs couple to inhibition
of adenylyl cyclase as well as to activation of PLC, and to
elevation of inositol triphosphate levels [30, 31]. Further-
more, an increase in intracellular Ca
2+ levels due to release
from intracellular stores and Ca
2+ influx has been described
[32, 33]. One interesting example of A3Rs’ functional role
is their involvement in acute neurotoxic situations and
interplay with A1Rs. Dunwiddie et al. [34] reported on the
potential of A3Rs to modify responses via A1Rs in the
hippocampus. The activation of hippocampal A3Rs induced
a desensitization of A1Rs on combined superfusion of Cl-
IB-MECA and adenosine. This phenomenon was thought to
reduce the protective effects of endogenous adenosine
caused by the lack of sensitivity of A1Rs. Further inves-
tigations on pyramidal cells of the rat cingulate cortex did
not confirm Dunwiddie et al.’s assumption [35]. In this
brain area, A1Rs and A3Rs did not show any interaction.
The receptor subtypes were unable to affect each other. The
discrepancy was taken to be a genetic phenomenon, such as
alternative splicing of the rat A3R transcript causing
distinguished pharmacological and functional properties in
the brain. Furthermore, Hentschel et al. [36] demonstrated
the involvement of A3Rs in inhibition of excitatory neuro-
transmission during hypoxic conditions, indicating a neuro-
protective action of endogenously released adenosine on
A3Rs in addition to A1Rs. Lastly, Lopes et al. [37] attempt-
ed to define the possible role of A3Rs in the rat hippo-
campus using experiments similar to those of Dunwiddie
et al. in non-stressful and stressful situations, with particular
attention to whether A3Rs control A1Rs. These data
suggested that no interaction between the two receptor
subtypes exist, but confirm that A3Rs do not affect synaptic
transmission on superfusion with A3R agonist Cl-IB-MECA
or A3R antagonist MRS 1191. The authors pointed out that
Cl-IB-MECA binds to A1Rs even at low nanomolar con-
centrations. Thus, the existence of an interaction between
A1Rs and A3Rs has to wait for reliable ligands.
Antagonistic interaction between A1Rs and A2ARs
A2ARs are widely distributed in the CNS, but local and
subcellular differences in allocation exist. They show high
levels in all subregions of the striatum and in the globus
pallidus. A2ARs are also expressed in neurons in the
neocortex and limbic cortex, but at a density a twentieth
of that found in basal ganglia [38]. Colocalization of A1Rs
and A2ARs was approved for glutamatergic nerve terminals
in the hippocampus [39]. In the striatum, A1R/A2AR
heteromers were found on synapses with spines of medium
spiny neurons and integrated in the presynaptic membrane
of glutamatergic terminals that represent the cortical-limbic-
thalamic input [18]. A1Rs and A2ARs modulate excitatory
synaptic transmission, albeit in an opposite manner. A1R
activation inhibited glutamatergic synaptic transmission
mainly through presynaptic inhibition of glutamate release,
while A2ARs have been shown to facilitate glutamatergic
synaptic transmission [40–42]. At first sight, stimulating
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influence on the mature CNS. However, problems arise due
to long-term desensitization of A1Rs. A2ARs do not up-
regulate after antagonist administration, but have a low
abundance in hippocampal and cortical areas compared with
A1Rs [40, 43, 44]. A1Rs and A2ARs cannot be regarded in
isolation from one another since cross talk between the
subtypes has been described several times [16, 17, 45–47].
A2AR activation by agonists caused A1R desensitization
resulting in decreased binding affinity for CPA in the
hippocampus in young adult rats. Controlling A1Rs by
A2ARs was mediated by protein kinase C in a cAMP-
independent manner. A2AR activation was seen to play a
role in fine-tuning A1Rs by attenuating the tonic effect of
presynaptic A1Rs located on glutamatergic nerve terminals
[46, 47]. In the striatal system, A1R/A2AR heteromers
became prominent to show an antagonistic reciprocal
interaction [18]. As in the hippocampus, A2AR stimulation
decreased the affinity of A1Rs for agonists. The A1R/A2AR
heteromer allows adenosine to perform a detailed modula-
tion of glutamate release [16, 48]. Regarding A1Rs and
A2ARs, basal conditions generate a low tone of endogenous
adenosine and cause A1R activation, in contrast to situations
of increased adenosine where A2AR activation becomes
dominant. When adenosine concentrations rise, as during
anoxia, likely also time appears to be important in regulating
A2A receptor activity, which means A2A receptors are “active”
under prolonged stimulation [49]. Finally, activation of the
A1R/A2AR heteromer contributes to A2ARs i g n a l i n gw h e n
adenosine levels are elevated and may provide a mechanism
to facilitate plastic changes in the excitatory synapse [18].
Interactions between adenosine and dopaminergic system
Dopamine is an important transmitter in basal ganglia and
is noted for influencing motor activity, playing an important
role in Parkinson’s disease. Adenosine-dopamine interac-
tions are complex and cannot be limited on functional
considerations of A1Rs. Intramembrane heteromeric recep-
tor-receptor interactions and the involvement of A2ARs in
influencing dopaminergic signaling have to be mentioned
due to the implications in the treatment of Parkinson’s
disease. Ginés et al. [50] described the formation of func-
tionally interacting heteromeric complexes between dopa-
mine D1 receptors (D1Rs) and A1Rs in mouse fibroblast
Ltk− cells cotransfected with respective cDNAs. Coaggre-
gation occurred when cells were pretreated with R-PIA as
A1R agonist, but was decreased by combined pretreatment
with R-PIA and SKF-38393, a D1R agonist. Furthermore,
the D1R agonist-induced cAMP accumulation was reduced
by combined pretreatment of D1R- and A1R agonist, but
remained unaffected when given alone, respectively. The
results confirmed an antagonistic interaction between A1Rs
and D1Rs that had already been observed by Ferré et al.
[51] in behavioral studies using reserpinized mice and
rabbits. In vivo and in vitro data on adenosine-dopamine
interactions were mostly obtained from investigations in the
basal ganglia and limbic regions [52, 53] due to the high
abundance of A1Rs, A2ARs, D1Rs, and D2Rs in these areas
and their involvement in the pathology of Parkinson’s
disease. The antagonistic interaction of combined receptor
activation seems to distinguish between adenosine and dopa-
mine receptor subtypes. While A1Rs communicate mainly
with the D1R subtype in strionigral-strioentopenduncular
neurons, A2ARa n dD 2R interaction occurs in striopallidal
neurons. Studies on mice and monkeys pretreated with
MPTP suggest that some degree of dopaminergic activity is
needed to obtain adenosine antagonistic-induced motor
activity. Furthermore, blockade of dopaminergic neurotrans-
mission counteracts the antagonistic effect induced by
adenosine [54]. Sufficient endogenous adenosine is present
interstitially in the substantia nigra pars reticulata to control
dopaminergic effects. The effects of adenosine are absent
when dopaminergic influence is suppressed [53]. Thus, it
seems that monotherapy with A2AR antagonists may only be
useful in the early stages of Parkinson’s disease, but could
support a therapeutic treatment with dopamine agonists in
advanced stages. A promising approach using these thera-
peutic strategies can be seen in istradefylline, an A2AR
antagonist that has since successfully passed clinical trials
[55]. However, A1R blockade may also contribute to an
increased dopamine release but this effect seems without
clinical relevance.
Relationship between A1Rs and NPY
Neuropeptide Y (NPY) is one of the most abundant
neuropeptides and exerts various functions on at least six
GPCR subtypes (Y1Rs-Y5Rs, y6Rs). Immunohistochemical
investigations revealed the appearance of the Y1R and Y5R
subtypes in the rat frontal cortex [56–58]. Activation of
NPY receptors results in an inhibition of excitatory synaptic
transmission, while a presynaptic influence on cortical
neurons has been postulated [59]. NPY receptors affect
pertussis toxin-sensitive G proteins, which inhibit adenylyl
cyclase and decrease cAMP levels. Inhibitory and facilitat-
ing effects on K
+ and Ca
2+ mobilization have also been
observed [60]. Receptor-receptor interactions between
Y1Rs have already been described, such as the antagonistic
interaction with galanin receptors in the hypothalamus of
the rat and their functional relevance for food intake. In
contrast, a facilitatory interaction between the two receptors
exists in the amygdala which may be of relevance for fear-
related behavior [61].
In the CNS, A1Rs and NPY receptors share some
similarities in distribution. Both A1Rs and Y1Rs are located
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inhibits glutamatergic neurotransmission [62]. This is
evidence for potential interaction between A1Rs and Y1Rs
that may modulate long-term desensitization of A1Rs
during pathophysiological situations. To investigate possi-
ble functional interactions, postsynaptic potentials (PSPs)
were generated by electrical field stimulation on pyramidal
neurons of layer V in the rat cingulate cortex as described
by Brand et al. [35] and Hentschel et al. [36]. The Y1R
agonist [F7,P34]pNPY inhibited the amplitude of PSPs.
The inhibitory effect was reversible and reproducible,
indicating that no desensitization appeared (Fig. 1a). An
additional decrease in PSP amplitude was observed when
NPY was superfused in combination with the A1R agonist
CPA (Fig. 1b).
The additional inhibition induced by CPA was in the
same range as that found with CPA alone (48.1±5% vs 55±
3%). NPY inhibited PSPs after blockading CPA-mediated
inhibitory effects by DPCPX. No significant changes
existed before and after blockading A1Rs (Fig. 2). The
results suggest that no interaction between A1Rs and Y1Rs
exist. Each neuromodulator contributes to inhibitory regu-
lation of excitatory neurotransmission. Regarding the
desensitization of A1Rs but not of Y1Rs, this may be im-
portant under pathophysiological conditions with increased
adenosine concentration in the synaptic cleft.
Interaction of A1Rs and P2Y1Rs
P2Y1Rs have been cloned and characterized in several
species including human and rat, whereas mRNA was
detected in various regions of the brain. The receptor
subtype can be activated by ATP, but ADP as a degradation
product of ATP is a more potent endogenous agonist.
Cellular signaling differs between A1Rs and P2Y1Rs since
A1Rs couple to Gi/0 and P2Y1Rs to Gq/G11. In fact, P2Y1Rs
can be assumed to exert stimulatory effects in cells. P2Y1R
signaling occurs in non-neuronal and non-muscular cell
types, as well as on neurons in the CNS [63] where a
colocalization of A1Rs and P2Y1Rs was demonstrated
immunohistochemically in rat brain cortex, hippocampus,
Fig. 2 Effect of neuropeptide Y (NPY) on the PSPs alone and in
combination with the selective A1R agonist N
6-cyclopentyladenosine
(CPA) after preincubation with the selective A1R antagonist 1,3-
dipropyl-8-cyclopentylxantine (DPCPX) (Sichardt et al., unpublished
results). The experimental procedure was similar to that shown in
Fig. 1. In the presence of NPY, PSPs were decreased by 35.4±7%.
Combined superfusion of NPY and CPA after preincubation with
DPCPX decreased PSPs by 32.7±8%. The depression was reversible
during washout. Data are expressed as mean ± SEM from n=5
independent experiments. *p<0.05 significant vs control;
#p<0.05
significant vs superfusion of CPA and DPCPX
Fig. 1 Effect of the selective Y1 agonist [F7,P34]pNPY as well as
neuropeptide Y (NPY) alone and in combination with selective A1R
agonist N
6-cyclopentyladenosine (CPA) on the amplitude of postsyn-
aptic potentials (PSPs) evoked by electrical field stimulation (0.2 Hz,
2 ms) in layer I of the rat cingulate cortex (Sichardt et al., unpublished
results). Intracellular recordings were performed in rat brain slices
using glass microelectrodes placed in pyramidal cells of layer V. a [F7,
P34]pNPY superfused for 5 min inhibits reversibly the PSPs by 34.6±
8%. Y1 antagonist BIBP3226 itself reduces the PSP by 23±10%,
whereas [F7,P34]pNPY has no inhibitory effect in the presence of the
antagonist. b NPY depresses PSPs by 28.6±0.7%. The combined
superfusion of NPYand CPA resulted in an additional depression of the
PSPs by 48.1±5%. The depressant effects of the two agonists were
reversible during washout. Data are expressed as mean ± SEM from n=
3 independent experiments. *p<0.05 significant vs control;
#p<0.05
significant vs NPY alone
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activation of an undefined P2YR by adenosine in patch
clamp and calcium imaging experiments on hippocampal
neurons [65]. Furthermore, extensive heteromerization
experiments have been conducted on cotransfected
HEK293 cells using immunoprecipitation, Western blotting,
and bioluminescence resonance energy transfer (BRET).
Receptor binding experiments in combination with cAMP
assays have also been described [64, 66–70]. These
respective studies confirmed heteromerization associated
with changes in the agonist binding and signaling compared
to monomer properties. The binding for selective A1R
agonists was decreased while the A1R antagonist binding
remained unaffected. Interestingly, ADP binding was
blocked by DPCPX but not by the P2Y1R antagonist,
suggesting an altered binding pocket on the A1R/P2Y1R
complex. The G protein-coupling was sensitive to pertussis
toxin and revealed a Gi/0 status for the heteromer. Although
colocalization of A1Rs and P2Y1Rs in several brain areas
has been demonstrated, there is still a lack of functional
investigations. Nevertheless, the physiological relevance of
this interaction has been postulated as follows: costorage and
release of ATP with neurotransmitters, such as glutamate or
noradrenaline, occurs in the CNS [71–73]. ADP, the degra-
dation product of ATP, acts as an A1R agonist due to the
activation of the A1R/P2Y1R complex and contributes to the
inhibitory modulation of excitatory synaptic transmission via
adenosine acting on A1Rs. This interaction can be assumed
as an additional mechanism for influencing and fine-tuning
synaptic neurotransmission.
Functional interaction with ionotropic receptors
Neuronal excitability is regulated by voltage and ligand-
gated ion channels. Ionotropic receptors also referred to as
ligand-gated ion channels (LGICs) are a group of intrinsic
transmembrane ion channels that open and close in response
to binding of a chemical messenger, as opposed to voltage-
gated ion channels or stretch-activated ion channels. Ion
channels are regulated by a ligand and are usually very
selective to one or more ions such as Na
+,K
+,C a
2+,o rC l
−.
These receptors located at synapses convert the chemical
signal of presynaptically released neurotransmitter directly
and very quickly into a postsynaptic electrical signal. Many
LGICs are additionally modulated by allosteric ligands by
channel blockers, ions, or membrane potential.
Nicotinic acetylcholine receptor serves as the prototyp-
ical LGIC [74] and consists of a pentamer of protein
subunits with two binding sites, which, when bound, alter
the receptor configuration and cause an internal pore to
open. This pore, permeable to Na
+ ions, allows them to
flow down their electrochemical gradient into the cell. With
a sufficient number of channels opening at once, the
intracellular Na
+ concentration rises to the point at which
the positive charge within the cell is sufficient to depolarize
the membrane, and an action potential is initiated [75].
Many important ion channels are ligand-gated, and they
show a great degree of homology at the genetic level. The
LGICs are classified into three superfamilies; the first—the
Cys-loop receptor family—is subdivided into the anionic
GABAA and glycine receptors on the one hand, and
cationic 5-HT3 serotonin and nicotinic acetylcholine recep-
tors on the other. The second group—ionotropic glutamate
receptors—consists of NMDA, kainate, and AMPA recep-
tors. The third group covers the ATP-gated channels—the
P2X receptors [76].
Adenosine is known to inhibit glutamatergic neurotrans-
mission by activation of presynaptic A1Rs [35]. This is
probably due to reduction of the calcium influx, possibly by
modulating both P/Q- and N-type presynaptic voltage-
dependent calcium channels, which in turn controls
transmitter release [77]. Furthermore, A1Rs have long been
known to mediate neuroprotection by reduction of excit-
atory effects at the postsynaptic level [10, 78, 79]. In
addition to its direct presynaptic and postsynaptic actions
on neurons, A1R interaction with NMDA [80–82, 84],
GABAA [85–88], and P2X receptors [80, 89–91] contrib-
utes to fine-tuning neuromodulation via adenosine.
Interaction between A1Rs and NMDA receptors
Glutamate is the major excitatory neurotransmitter in the
mammalian central nervous system. In most brain areas,
glutamate mediates fast synaptic transmission by activating
ionotropic receptors of the AMPA, kainate, and NMDA
type. Additionally, NMDA receptors play a critical role in
synaptic plasticity, synaptic development, and neurotoxicity.
Recent studies suggest that some NMDA-mediated actions
are altered or mediated by adenosine. Synaptic currents
mediated by glutamate in rat substantia nigra pas reticulata
neurons were reduced by adenosine acting via A1Rs. The
inhibitory action was not mediated by a postsynaptic site
since adenosine did not block currents evoked by local
application of glutamate [86].
NMDA is known to increase the extracellular level of
adenosine via bidirectional adenosine transporters or from
released adenine nucleotides degraded by a chain of
ectonucleotidases [92, 93]. On the other hand, endogenous
adenosine present in the extracellular fluid of hippocampal
slices tonically inhibits NMDA receptor-mediated dendritic
spikes as well as AMPA/kainate receptor-mediated syn-
chronized EPSPs by activation of A1Rs in CA1 pyramidal
cells [81]. In line with these results, it has been shown that
the tonic activation of A1Rs by ambient adenosine depressed
field potentials in the striatum. The effect of adenosine in
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A1R knockout mice and clearly demonstrates the involve-
ment of A1Rs. The involvement of A1Rs was also supported
by experiments using the selective receptor ligand 2-CA. In
isolated rat hippocampal pyramidal cells [95] and in bipolar
cells of the retina [96], 2-CA decreased inward currents
induced by iontophoretic application of NMDA.
Another interesting interaction concerns NMDA precon-
ditioning to protect against glutamate neurotoxicity. The
A1R antagonist 8-CPT has been shown to prevent neuro-
protection evoked by NMDA preconditioning against
glutamate-induced cellular damage in cerebellar granule
cells [83]. In this study, the functionality of A1Rs was not
affected by NMDA preconditioning, but this treatment
promoted A2AR desensitization in concert with A1R
activation [83]. These results are in line with other studies
indicating that adenosine downregulates excitatory and
inhibitory synaptic transmission in several brain areas
through activation of A1Rs and A2AR[ 97, 98]. Further-
more, activation of A1Rs mediates reversal of long-term
potentiation (LTP) produced by brief application of NMDA
in hippocampal CA1 neurons [99].
Fig. 3 Schematic representation
of possible interactions of A1Rs
with metabotropic receptors.
Heteromerization between pre-
synaptically located A1Rs and
A2ARs, D1Rs, and P2Y1Rs
causes changes in influencing
glutamate release by adenosine.
Cross talk between A1Rs and
P2Y1Rs contributes mainly to
triggering fast attenuation of
transmitter release, whereas
ADP acts as a ligand on the
heteromer. During elevated
adenosine levels, A2AR signal-
ing becomes dominant in the
A1R/A2AR complex, providing
enhancement of glutamate
release. The A1R/D1R hetero-
mer requires both adenosine and
dopamine to be activated and
inhibits transmitter release
Fig. 4 Schematic representation
of possible interactions of A1Rs
with ionotropic receptors con-
tributing to the fine-tuning of
neurotransmission. Adenosine
acting via presynaptic A1Rs may
attenuate the influx of Ca
2+
through voltage-dependent cal-
cium channels and thus decrease
the release of glutamate and
GABA, which inhibits or facili-
tates the activation of postsyn-
aptically located NMDA
receptors, respectively. Adeno-
sine acting through postsynaptic
A1Rs may activate KATP, which
leads to hyperpolarization of
postsynaptic neurons and inhib-
its directly the activity of
NMDA and GABAA receptors
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sine may interact with NMDA-induced cellular events.
Adenosine can affect glutamatergic transmission via both
presynaptic and postsynaptic mechanisms by activating
A1Rs [78]. NMDA receptors and A1Rs interact to down-
regulate glutamate release presynaptically in pyramidal
cells of the cingulate cortex [35], neurons of the hippo-
campus [100], and striatal neurons [84]. Another putative
mechanism is related to postsynaptic A1Rs; adenosine
elevates the threshold to open NMDA receptor-operated
channels by antagonizing membrane depolarization [101].
Interaction between A1Rs and GABAA receptors
Fast synaptic inhibition in the brain and spinal cord is largely
mediated by GABAA receptors that are also targeted by
drugs such as benzodiazepines, barbiturates, neurosteroids,
and some anesthetics. The modulation of their function will
have important consequences for neuronal excitation [102].
One accepted means of modifying the efficacy is a
functional interaction with adenosine. Adenosine may have
an effect on either presynaptic GABA release in interneur-
ons and/or on postsynaptic GABAA receptors in projection
neurons. The site of action may be studied electrophysio-
logically by inducing fast inhibitory postsynaptic potentials
(IPSPs) or application of GABA directly onto the cell.
Adenosine and selective A1R agonist CHA reduced the
amplitude of the fast IPSP in lateral amygdala slice
preparations. The effect of CHA was blocked by DPCPX,
indicating the involvement of A1Rs. Additionally, adenosine
did not block currents evoked by local application of
GABA [85]. Thus, the modulatory effect of adenosine on
the GABAergic neurotransmission appears to take place on
a presynaptic site by inhibiting GABA release from nerve
terminals [85, 86]. The assumption that the activation of
A1Rs can presynaptically modulate inhibitory postsynaptic
responses agrees with findings in several brain areas, such as
the thalamus [87], suprachiasmatic and arcuate nucleus [88],
and substantia nigra pars compacta [86].
There is some evidence that activation of A1Rs is also
involved in GABAA receptor downregulation, implying a
facilitation of the neurotransmission on a postsynaptic site.
GABA but not adenosine evoked an inward current in rat
sacral dorsal commissural neurons (SDCN). The GABA-
induced current was significantly reduced be adenosine.
CHA and DPCPX, but not selective ligands for A2ARs,
mimicked or blocked the inhibitory effect of adenosine,
respectively [103]. Adenosine and muscimol induced a
concentration-dependent reduction in the amplitude of
population potentials in hippocampal slices. Additionally,
adenosine potentiated the ability of muscimol to inhibit
evoked potentials, which were blocked by the A1R-selective
antagonist 8-CPT. The effects of adenosine as well as
muscimol were reduced by the chloride channel blocker
DIDS, indicating the ability of adenosine to regulate the
GABAA chloride channel by activation of A1Rs [104].
Sebastiao’s group studied the mechanisms by which
GABA modulates adenosine-mediated effects and found
that endogenous GABA exerts an inhibitory effect through
GABAA receptors via a predominant adenosine-mediated
action in the hippocampus. The authors concluded that
there is an A1R-mediated ability to inhibit synaptic trans-
mission [19]. Further, this study showed that the blockade
of GABAergic inhibition induced the release of NO, which
was able to potentiate the inhibitory action of adenosine.
They therefore suggested that the modulation of the A1R-
mediated response by activation of GABAA receptors
occurs indirectly via NO [19].
Activation of GABAA receptors is effective in limiting
neuronal ischemic damage [105] and endogenous adeno-
sine that arises during hypoxia, and acts neuroprotectively
partly by activating A1Rs [36]. Therefore, the contribution
and potential interactions of GABA and adenosine as
modulators of synaptic transmission during hypoxia has
been investigated. Activation of A1Rs inhibits the release of
GABA from the ischemic cerebral cortex in vivo [106]. In
contrast, the administration of an A1R agonist in the
hippocampus failed to affect the release of GABA during
ischemia [107]. In the light of these controversial results,
Fig. 5 Neurological disorders where A1R interactions may play a role
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investigated in the CA1 area of rat hippocampal slices using
selective A1R antagonists [108]. Indeed, activation of A1R
and GABAA receptors is partly involved in the inhibition of
synaptic transmission during hypoxia. The action of GABA
becomes evident when A1Rs are blocked. Regarding the
desensitization of A1Rs during hypoxia [109, 110], it may
be assumed that GABAA-mediated inhibition of the
synaptic transmission is evident when the A1R is desensi-
tized or downregulated [108].
Comodulation by A1Rs and GABAA receptors was also
suggested in acute cerebellar ethanol-induced ataxia. Using
GABAA and A1R agonists and antagonists, respectively, a
functional similarity between GABAA receptors and A1Rs
has been shown even though both receptor types are known
to couple to different signaling systems [111]. This provides
conclusive evidence that A1Rs and GABAA receptors both
play a comodulatory role in ethanol-induced cerebellar ataxia
without any direct interaction.
Functional interaction between A1Rs and P2X receptors
P2X receptors are ligand-gated ion channel receptors; seven
subunits (P2X1-P2X7) have been identified [63]. The P2X
receptor subunits show many differences in localization,
pharmacology, kinetics, and signaling pathways [112, 113].
The P2X1 to P2X6 receptors have 379–472 amino acids,
with a predicted tertiary structure of transmembrane seg-
ments, a large extracellular loop and intracellular C and N
termini. The P2X2,P 2 X 4, and P2X4/P2X6 receptors appear
to be the predominant neuronal types [91]. These subunits
may occur as homooligomers or as heterooligomeric
assemblies of more than one subunit. The P2X7 receptor
has a similar structure, but with a much larger intracellular
C terminus. This contrasts strikingly with any of the other
known ligand-gated ionotropic receptors [114]. P2X7
subunits do not form heterooligomeric assemblies, but are
involved in mediating apoptosis and necrosis in glial cells
and possibly neurons.
Interaction between adenosine receptor-mediated and P2
receptor-mediated effects have been shown to occur in
neuronal and non-neuronal cells [80]. Both adenosine and
ATP induce astroglial cell proliferation and formation of
reactive astrocytes [89]. In hippocampus, adenosine and
ATP are released on stimulation and are potent neuronal
transmission inhibitors [115, 116]. It should be pointed out
that the interpretation of effects induced by both is difficult
since ATP is degraded enzymatically to adenosine [38].
Adenosine is formed by extracellular catabolism of released
ATP via the ectonucleotidase pathway [90, 117]. The role
of the ectonucleotidases in forming adenosine is difficult to
study since this system is extremely efficient, and it is
difficult to block an enzyme system. The experimental
paradigm used by Cunha et al. [118] demonstrates that ATP
has to be converted outside the cell into adenosine to exert
its inhibitory effects on hippocampal synaptic transmission.
The inhibitory effect of ATP was not modified by the P2
receptor antagonist suramin, but was attenuated by the ecto-
5’-nucleotidase inhibitor and was nearly prevented by the
adenosine A1R antagonist DPCPX, whereas dipyridamole,
an inhibitor of adenosine uptake, potentiated the inhibitory
effect of ATP [118]. These results offer evidence for
localized catabolism of adenine nucleotides followed by
substrate channeling to A1Rs. This localized catabolism may
mask the adenosine-mediated ATP effect [119]. Recently it
was demonstrated that the exogenous application of ATP or
ATPχS reduced the hippocampal neurotransmission. The
inhibitory effect was blocked by the selective A1R antag-
onist DPCPX and was potentiated by different ecto-ATPase
inhibitors [120]. These results suggest that the synaptic
inhibition may consist of an inhibitory purinergic compo-
nent of ATP itself in addition to degradation to adenosine.
Interaction with neuronal ATP-sensitive K
+ channels
ATP-sensitive K
+ channels (KATP) are widely expressed in
the cytoplasmic membrane of neurons and couple cell
metabolism to excitability [121]. These channels are
regulated by the intracellular ATP/ADP ratio [122] and
modulated by many endogenous mediators, including
adenosine, via A1Rs. Activation of A1Rs inhibited the
activity of inspiratory neurons in the brainstem by opening
KATP in neonatal mice [123]. A1R stimulation promotes
KATP activity in principal dopamine neurons in the
substantia nigra pars compacta [124] and hippocampus
[125]. In contrast, one recent study has demonstrated that
adenosine induces internalization of KATP, resulting in a
decrease in KATP-mediated response in the hippocampus
[126]. The discrepancy might be due to the additional
activation of A2ARs by adenosine located in hippocampus,
but not in the substantia nigra pars compacta [127]. In
addition to the inhibitory effect on the presynaptic site, the
activation of A1Rs acts as an inhibitory modulator to
electrical activity on the postsynaptic site, and this effect
has been attributed to enhancement of KATP activity. The
modulating effect on the membrane potential may differ
depending on the brain regions, as neuronal KATP is
heterogeneous in different neurons.
A1R interactions—new approaches for neurological
disorders
By activation of its receptors, adenosine regulates many
pathophysiological processes, particularly in excitable
Purinergic Signalling (2007) 3:285–298 293tissues of the brain (Fig. 3). Its widespread functions in the
body include regulation of seizure susceptibility [128, 129],
neuroprotection [40], regulation of pain perception [130],
sleep induction [131], and involvement in Parkinson’s
disease [132]. There is increasing evidence that the
functional interaction of A1Rs with other neuronal receptors
may contribute to fine tuning in synaptic transmission, and
A1R agonists may represent a useful therapeutic approach
for the treatment of some neurological disorders by
regulating homeostasis in transmitter systems. However,
the use of A1R agonists has not proved clinically useful due
to mainly cardiovascular side effects as well as low brain
permeability. Pioneering experimental approaches have been
evaluated using focal drug delivery in epilepsy models. One
experimental study has used intraventricular implantation of
an adenosine-releasing synthetic polymer [128]. In a later
study, Guttinger et al. [133] used encapsulated C2C12
myoblasts that were engineered to release adenosine by
disruption of their adenosine kinase gene [133]. The local
delivery of adenosine by implanted cells appears to be a
promising strategy for the control not only for affecting
seizure activity but also other neurodegenerative diseases
with dysregulated synaptic neurotransmission.
Concluding remarks
As a consequence of its ubiquitous distribution and because
of its linkage to the energy pool, adenosine has evolved as
an important messenger in extracellular signaling. Modifi-
cations in extracellular adenosine levels with subsequent
alterations in the activation of its receptors interferes with
the action of other receptor systems. Figure 4 summarizes
possible interactions of A1Rs with metabotropic receptors,
Fig. 5 shows the interactions between A1Rs and ionotropic
receptors as well as with KATP, and Fig. 3 shows the neuro-
logical disorders where A1R interactions may play a role.
There is evidence that various regulatory mechanisms
exist as well as multiple mechanisms that act independently
of each other on the same cell depending on the brain
region and cell type. The overaction and redundancy
principle ensures transmitter homeostasis under pathophys-
iological conditions in a special time window. The function
of adenosine receptors in the regulation of the synaptic
transmission is complex.
The key receptor in regulation of the neuronal transmis-
sion may be the A2AR, whereas the interaction of the A1R
with metabotropic and ionotropic receptors as well as with
KATP serves as fine-tuning to inhibit synaptic transmission,
as mentioned by Sebastiao and Ribeiro [80]. A1Rs may
play a nonessential role in normal physiology as demon-
strated in mice lacking the A1Rs [134]. However, they play
an important protective role under pathophysiological
conditions especially during hypoxia. The activation ini-
tiates a fast inhibition of the glutamatergic neurotransmis-
sion and the receptor interactions may contribute to its
maintenance or can support the A1R-mediated effects.
Most of our knowledge on receptor-receptor interactions
involving the A1R results from experiments on cell cultures,
slice preparation or, to a lesser extent, from in vivo expe-
riments where regulation can be studied in principle or new
drug targets can be characterized. These findings may
contribute to a better understanding of disturbances in trans-
mitter homeostasis. As our understanding of the complexity
of receptor signaling and interaction develops, we may well
gain new perspectives in new drug development. The
clinical relevance of the testing models has often been
questioned, however. Discordance between studies on cells
and animal and human studies may be due to bias or failure
of models to mimic clinical disease to an adequate degree.
There are new techniques such as neuroimaging, nanotech-
nology, siPCR, and new selective receptor ligands that will
help to overcome some of these aspects in the near future.
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